Neck arteriosclerosis
Conditions
Interventions
Experimental group:Ginkgo biloba oral liquid, 2 bottles (10mL) twice daily for 24 weeks
Control group:Ginkgo biloba oral liquid mimicry, 2 bottles (10mL) twice daily for 24 weeks
Sponsors
Xiyuan Medicine, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. According to the diagnostic criteria of intimal thickening or plaque formation by carotid ultrasound, the stenosis rate of carotid artery was 50%; 2. According to the diagnostic standard of blood stasis syndrome of TCM (referring to the practical diagnostic standard of blood stasis syndrome of China Association of Integrated Traditional Chinese and Western medicine); 3. Aged 18-65 years, gender unlimited; 4. Give informed consent and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with acute cardiac cerebrovascular disease; 2. History of previous cerebral hemorrhage; 3. Transaminase 1.5 times higher than normal or abnormal renal function; 4. High-risk patients with stent or surgical indication, carotid artery stent (CAS) or carotid endarteretomy (CEA) Carotid endarterectomy; 5. Active bleeding or high risk of bleeding (such as those with definite diagnosis of peptic ulcer and bronchiectasis or tuberculosis within the last 3 months); 6. Patients with severe arrhythmia, atrial fibrillation and heart failure; 7. Patients who are allergic to the experimental drugs and their components or belong to an allergic constitution; 8. Patients who had been scheduled for surgical operation within this study cycle or within 10 days after the end of this study; 9. Patients with hypertension whose blood pressure > 180/110 mmhg could not be controlled by the optimal treatment regimen; 10. Recent use of Antiplatelet drug or anticoagulants such as phenylpropanol, warfarin, aspirin, etc.; 11. Patients with severe coronary artery disease: coronary artery stenosis >= 75% confirmed by coronary angiography or coronary CT angiography, or within 1 year after percutaneous coronary intervention (PCI); 12. Pregnant, planned pregnant or lactating women; 13. Those who have participated or are participating in other clinical studies within 3 months; 14. The researcher judged that it was not suitable to take part in this experiment or easy to cause lost follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Common carotid arteries (CCAs) mean IMT (mean-IMT-CCA) values before and after treatment;Average and maximum IMT values for the bulbous and extracranial internal carotid arteries (ICA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factors;Four items of coagulation;Total points for bilateral carotid plaques;Carotid artery stenosis rate;Plaque size;Plaque area; | — |
Countries
China
Contacts
Public ContactXiaojuan Ma
Xiyuan Medicine, China Academy of Chinese Medical Sciences
Outcome results
None listed